Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2025 04:05 ET | Source: Research and Markets

Congestive Heart Failure (CHF) Epidemiology Forecast 2025-2034 Across the US, UK, France, Italy, Spain, Germany, Japan, and India

Dublin, June 11, 2025 (GLOBE NEWSWIRE) -- The "Congestive Heart Failure (CHF) Epidemiology Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.Heart failure is a...
December 09, 2024 09:49 ET | Source: Research and Markets

Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy (CRT) - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ...
December 09, 2021 09:00 ET | Source: Renova Therapeutics

Renova Therapeutics Appoints Dr. Vijay Mahant as Its CEO

CARLSBAD, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Dr. Mahant brings a wealth of knowledge and experience to his role as the CEO. He is a scientist, an inventor (awarded 32 international patents)...
February 04, 2020 08:05 ET | Source: Asklepios BioPharmaceutical, Inc.

AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure

RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor...
April 15, 2019 04:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
February 25, 2014 17:00 ET | Source: Mesoblast

Mesoblast Reports Strong Half-Year Financial Results

NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
February 02, 2014 20:06 ET | Source: Mesoblast

Boardroom Radio Interview with Mesoblast Chief Executive

NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...
October 30, 2013 18:41 ET | Source: Mesoblast

FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS

NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...